Inside This Issue: Huntington's Disease
Top News Alerts: Product Updates, Deals & Financings
Featured Topic: AD annual wellness screening
Company Spotlight: Avicena
Subscribe now to access over 30 articles covering developments in drugs, devices and diagnostics for the brain and nervous system.
Market Highlights: Investor Dollars Shift from Private to Public in 2010
NeuroInsights data indicates that venture capital investment in neurotech plummeted in 2010. Private drug, device, and diagnostic companies with a neuroscience related product in development raised an estimated $840 million, only a little more than half of the $1.6 billion raised in 2009. Public investors, on the other hand, flocked to neurotech in 2010. The NASDAQ NeuroInsights Neurotech Index was up 32% for the year compared to only 15% for the NASDAQ Biotech and 13% for the S&P 500....
The Hunt for Huntington's Therapies
Huntington's disease, also known as Huntington's chorea or simply chorea is an autosomal dominant, single gene disorder that leads to progressive neurodegeneration and death. The word chorea derives from Greek and means dance. It is used to describe the involuntary dance-like movements that are a characteristic symptom of HD. The cause of HD, which affects both genders equally, is a mutation in a gene called huntingtin (HTT) that codes for a protein (Htt) of the same name. The exact function of the protein is unknown but it is expressed in most tissues. In patients with HD, many organ systems show evidence of the disorder, although specific neurological symptoms dominate the clinical picture. It is not well understood why neurons in the basal ganglia exhibit the greatest sensitivity to damage, thereby giving rise to the characteristic symptomatology. .. This article outlines Huntington's disease, current treatments and therapies in development ...
Avicena: Flying Under the Radar
Avicena Group (AVCE.PK) is a small company founded in the mid 1990's, based on science out of Paul Schimmel's lab. Dr. Schimmel's research focused on how cells regulate their various energy systems. The company’s stock plummeted in 2007 resulting in a move to the Pink Sheets and near zero trading volume. To the naked eye it appeared that the company might have called it quits...
Companies Covered In This Issue Include: Accera, Active Biotech, Acura, Adimab, Affiris, Alexza Pharma, Arena Pharma, Biogen Idec, Biotie therapies, Brainscope, California Stem Cell, Celvive, Cephalon, Chase, Corcept, Cynapsus, DiaGenic, Elekta, Eli Lilly, EmSense, Enteromedics, Euthymics Bioscience, Galapagos, GE Healthcare, Geron, GSK, Impax, InVivo Therapeutics, Johnson and Johnson, King Pharma, Lundbeck, MAP, Medistem, Merck, Mesoblast, Neuralstem, Neuraltus, Neurimmune, Neurologix, Neuronetrix, Neurotrax, NeuroVive, Neurowave, Nevro, Orexigen, Panoptica, Pfizer, Provesica, QLT, Ramius, Regenesance, Rexahn, Roche, Stem Cell Therapeutics, St. Jude Medical, Supernus, Teva, Transition Therapeutics, United Biosource, Uroplasty, Corporation, Vernalis, Vistagen, Vivus, Xention, Zenobia
Subscribe now:
|
|
